Johns Hopkins Researchers Develop Nasal DNA Vaccine Targeting Tuberculosis

Researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have developed a new DNA-based vaccine aimed at treating tuberculosis (TB), one of the world’s most persistent infectious diseases. The vaccine, which is administered nasally, represents a novel therapeutic approach and was recently detailed in the *Journal of Clinical Investigation*. This advancement seeks to address ongoing challenges in TB treatment and prevention.

The nasal DNA vaccine is designed to stimulate a robust immune response directly in the respiratory system, where TB infections typically begin. Unlike traditional TB vaccines, this method focuses on delivering genetic material that prompts cells to produce antigens capable of triggering immunity against the disease. Researchers believe this targeted delivery could enhance protection while potentially reducing side effects associated with other vaccination methods. The study highlights the potential for this approach to complement existing treatments and improve outcomes for individuals affected by TB worldwide.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 1, 2026

Author

GOAI